HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 1238097

a BET bromodomain inhibitor with antineoplastic activity

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        BAY 1238097: 3

Experts

1.	Ocker, Matthias: 2 articles (01/2019 - 01/2017)
2.	Haendler, Bernard: 2 articles (04/2018 - 01/2017)
3.	Siegel, Stephan: 2 articles (04/2018 - 01/2017)
4.	Benson, Neil: 1 article (01/2019)
5.	Ewerton, Flavio: 1 article (01/2019)
6.	Herbschleb, Karin: 1 article (01/2019)
7.	Massard, Christophe: 1 article (01/2019)
8.	Middleton, Mark: 1 article (01/2019)
9.	Poelman, Martine: 1 article (01/2019)
10.	Postel-Vinay, Sophie: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "In this phase I, open-label, non-randomised, multicentre study, patients with cytologically or histologically confirmed advanced refractory malignancies received oral BAY 1238097 twice weekly in 21-day cycles using an adaptive dose-escalation design at a starting dose of 10 mg/week. " 01/01/2019 - "A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated dose and recommended phase II dose of the BET inhibitor BAY 1238097 in patients with advanced malignancies. "
2.	Lymphoma (Lymphomas) 01/01/2017 - "In conclusion, the BET inhibitor BAY 1238097 presented promising anti-lymphoma preclinical activity in vitro and in vivo, mediated by the interference with biological processes driving the lymphoma cells. " 01/01/2017 - "BAY 1238097 showed anti-proliferative activity in a large panel of lymphoma-derived cell lines, with a median 50% inhibitory concentration between 70 and 208 nmol/l. " 01/01/2017 - "Here, we have characterized the anti-tumour activity of the novel bromodomain and extra-terminal (BET) inhibitor BAY 1238097 in preclinical lymphoma models. " 01/01/2017 - "Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/10/2018 - "Here, we preclinically evaluate the effect of BET inhibition making use of a new BET inhibitor, BAY 1238097, against Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC) models harboring RAS mutations both in vivo and in vitro. "
4.	Adenocarcinoma 04/10/2018 - "Here, we preclinically evaluate the effect of BET inhibition making use of a new BET inhibitor, BAY 1238097, against Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC) models harboring RAS mutations both in vivo and in vitro. "